Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Furio Colivicchi(Ospedale San Filippo Neri), Luigi Tarantini(Santa Maria Nuova Hospital), Giuseppina Gallucci, Stefania Angela Di Fusco(ASL Roma), Paolo Trambaiolo(Ospedale Sandro Pertini), Antonella Moreo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Fabiana Lucà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Michele Massimo Gulizia(Ospedale Garibaldi), Giulia Russo(University of Catania), Vincenzo Quagliariello(Cancer Institute (WIA)), Giovanna Geraci(Ospedale Vincenzo Cervello), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Fabio Maria Turazza, Iris Parrini(A. O. Ordine Mauriziano di Torino), Fabrizio Oliva(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Maria Laura Canale(Ospedale Versilia), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Chiara Lestuzzi
Cited by 5
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
In silico clinical trials: concepts and early adoptions
|Briefings in Bioinformatics|2018|267
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis
|Heart|2015|153
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116